Hyperinflammation due to COVID-19 and the Targeted Use of Interleukin-1 Inhibitors.
作者信息
Gasparyan Armen Yuri, Kitas George D
机构信息
Departments of Rheumatology and Research and Development, Dudley Group NHS Foundation Trust (Teaching Trust of the University of Birmingham, UK), Russells Hall Hospital, Dudley, West Midlands, United Kingdom.
Centre for Epidemiology versus Arthritis, University of Manchester, Manchester, United Kingdom.
出版信息
Mediterr J Rheumatol. 2022 Jun 30;33(2):173-175. doi: 10.31138/mjr.33.2.173. eCollection 2022 Jun.
Abstract
摘要
相似文献
1
Hyperinflammation due to COVID-19 and the Targeted Use of Interleukin-1 Inhibitors.
Mediterr J Rheumatol. 2022 Jun 30;33(2):173-175. doi: 10.31138/mjr.33.2.173. eCollection 2022 Jun.
2
Autoinflammatory manifestations in adult patients.
Clin Exp Immunol. 2022 Dec 31;210(3):295-308. doi: 10.1093/cei/uxac098.
3
[Role of interleukin-1 in human diseases: pharmacotherapy prospects: A review].
Ter Arkh. 2022 Oct 12;94(8):999-1005. doi: 10.26442/00403660.2022.08.201781.
4
Systematic Review of Safety and Efficacy of IL-1-Targeted Biologics in Treating Immune-Mediated Disorders.
Front Immunol. 2022 Jul 6;13:888392. doi: 10.3389/fimmu.2022.888392. eCollection 2022.
5
Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: An observational cohort study.
J Allergy Clin Immunol. 2021 Feb;147(2):561-566.e4. doi: 10.1016/j.jaci.2020.11.006. Epub 2020 Nov 19.
6
Efficacy and Safety of Anakinra Plus Standard of Care for Patients With Severe COVID-19: A Randomized Phase 2/3 Clinical Trial.
JAMA Netw Open. 2023 Apr 3;6(4):e237243. doi: 10.1001/jamanetworkopen.2023.7243.
7
Treatment of Inflammatory Diseases with IL-1 Blockade.
Curr Otorhinolaryngol Rep. 2018;6(1):1-14. doi: 10.1007/s40136-018-0181-9. Epub 2018 Mar 7.
8
Drug survival of anakinra and canakinumab in monogenic autoinflammatory diseases: observational study from the International AIDA Registry.
Rheumatology (Oxford). 2021 Dec 1;60(12):5705-5712. doi: 10.1093/rheumatology/keab419.
9
Long-term safety and efficacy of anakinra and canakinumab in patients with familial Mediterranean fever: a single-centre real-life study with 101 patients.
Clin Exp Rheumatol. 2021 Sep-Oct;39 Suppl 132(5):30-36. doi: 10.55563/clinexprheumatol/815tdt. Epub 2021 Jun 21.
10
Current evidence on the use of anakinra in COVID-19.
Int Immunopharmacol. 2022 Oct;111:109075. doi: 10.1016/j.intimp.2022.109075. Epub 2022 Jul 20.
引用本文的文献
1
Do Interleukin-1 and Interleukin-6 Antagonists Hold Any Place in the Treatment of Atherosclerotic Cardiovascular Disease and Related Co-Morbidities? An Overview of Available Clinical Evidence.
J Clin Med. 2023 Feb 6;12(4):1302. doi: 10.3390/jcm12041302.
本文引用的文献
1
COVID-19 infection among patients with autoinflammatory diseases: a study on 117 French patients compared with 1545 from the French RMD COVID-19 cohort: COVIMAI - the French cohort study of SARS-CoV-2 infection in patient with systemic autoinflammatory diseases.
RMD Open. 2022 May;8(1). doi: 10.1136/rmdopen-2021-002063.
2
Inflammasome activation in infected macrophages drives COVID-19 pathology.
Nature. 2022 Jun;606(7914):585-593. doi: 10.1038/s41586-022-04802-1. Epub 2022 Apr 28.
3
Clinical outcomes of COVID-19 patients with rheumatic diseases: a retrospective cohort study and synthesis analysis in Wuhan, China.
Clin Rheumatol. 2022 Jun;41(6):1899-1910. doi: 10.1007/s10067-022-06086-2. Epub 2022 Feb 16.
4
Post-COVID-19 arthritis: is it hyperinflammation or autoimmunity?
Eur Cytokine Netw. 2021 Dec 1;32(4):83-88. doi: 10.1684/ecn.2021.0471.
5
Interleukin-1 blocking agents for treating COVID-19.
Cochrane Database Syst Rev. 2022 Jan 26;1(1):CD015308. doi: 10.1002/14651858.CD015308.
6
A prospective multicenter study assessing humoral immunogenicity and safety of the mRNA SARS-CoV-2 vaccines in Greek patients with systemic autoimmune and autoinflammatory rheumatic diseases.
J Autoimmun. 2021 Dec;125:102743. doi: 10.1016/j.jaut.2021.102743. Epub 2021 Oct 28.
7
Severe COVID-19 is characterized by the co-occurrence of moderate cytokine inflammation and severe monocyte dysregulation.
EBioMedicine. 2021 Nov;73:103622. doi: 10.1016/j.ebiom.2021.103622. Epub 2021 Oct 20.
8
Different Profiles of Antibodies and Cytokines Were Found Between Severe and Moderate COVID-19 Patients.
Front Immunol. 2021 Aug 19;12:723585. doi: 10.3389/fimmu.2021.723585. eCollection 2021.
9
Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial.
Nat Med. 2021 Oct;27(10):1752-1760. doi: 10.1038/s41591-021-01499-z. Epub 2021 Sep 3.
10
Predictors of hospitalization for COVID-19 in patients with autoimmune rheumatic diseases: results from a community cohort follow-up.
Clin Rheumatol. 2021 Nov;40(11):4725-4734. doi: 10.1007/s10067-021-05833-1. Epub 2021 Jun 30.
Zotero 插件